HER2: An emerging biomarker in non-breast and non-gastric cancers

Omar, Nasiroh; Yan, Benedict; Salto–Tellez, Manuel

doi:10.1016/j.pathog.2015.05.002

Cited by 32 publications

(23 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HER2 is a receptor tyrosine kinase that is frequently overexpressed by cancers, including breast, salivary gland, and bone [ 79 , 80 ]. HER2 expression is often associated with poor prognosis, as HER2 signaling has been shown to directly activate pathways responsible for tumor growth and survival [ 79 ]. While antibody-based therapies targeting HER2 have been developed, many patients still experience recurrence after treatment.…”

Section: Listeria Vaccines In Clinical Trialsmentioning

confidence: 99%

Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress

2018

View full text Add to dashboard Cite

Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed utilizing modified Listeria as a tool for generating immune responses against a variety of cancers. Moreover, over a dozen clinical trials testing Listeria cancer vaccines are currently underway, which will help to understand the utility of Listeria vaccines in cancer immunotherapy. This review aims to summarize current views on how Listeria-based vaccines induce potent antitumor immunity and the current state of Listeria-based cancer vaccines in clinical trials.

show abstract

Section: Listeria Vaccines In Clinical Trialsmentioning

confidence: 99%

Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress

2018

View full text Add to dashboard Cite

show abstract

“…Further studies have shown that the overexpression of HER2 occurs in some other cancers, such as stomach, ovary, colon, bladder, lung, uterus, head, neck and esophagus. Apart from its role in promoting cancer, this receptor can be used in targeted therapies . Several therapy approaches have been used for breast cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Apart from its role in promoting cancer, this receptor can be used in targeted therapies. [4][5][6] Several therapy approaches have been used for breast cancer treatment. Surgery has long been used to remove tumor tissue.…”

Section: Introductionmentioning

confidence: 99%

Design and construction of a recombinant lentiviral vector with specific tropism to human epidermal growth factor‐overexpressed cancer cells: Developing a new retargeting system for lentivirus vectors

Ebrahimabadi

Shahbazi

Akbari

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background Targeting of specific tissues and cells by viruses is one of the challenges faced by researchers. Lentiviral vectors (LVs) are one of the most promising gene delivery systems in cancer gene therapy. Therefore, we aimed to design a novel lentiviral delivery system that expresses anti‐ human epidermal growth factor 2 (HER2) designed anykrin repeat protein (DARPin) on the vector envelope to create a pseudotyped lentivirus for targeting HER2‐positive cancer cells. Methods A helper plasmid producing the viral vector envelope containing anti‐HER2 DARPin‐G3 was constructed. LV was produced by transfer vector containing green fluorescent protein (GFP) gene and helper plasmids in human embryonic kidney 293 cells. The human breast cancer cell lines SKBR3 (normal and with inhibited endocytosis) (HER2‐positive) and MDA‐MB‐231 (HER2‐negative) were transduced by the recombinant viral vector. The GFP‐based transduction rate was determined by flow cytometry and fluorescence microscopy. Results The anti‐HER2 DARPin concentration in DARPin‐LVs was significantly higher than the envelope G glycoprotein of the vesicular stomatitis virus‐LVs (non‐anti‐HER2 control) (p < 0.0001). In flow cytometry assays, the percentage of transduction by recombinant LV was significantly higher in SKBR3 cells than in SKBR3 cells with inhibited endocytosis (p = 0.0074) and MDA‐MB‐231 cells (p = 0.0037). In fluorescence microscopy assays, the percentage of transduction by new LV was significantly higher in SKBR3 cells than in SKBR3 cells with inhibited endocytosis (p = 0.0026) and MDA‐MB‐231 cells (p = 0.0014). Conclusions We constructed a new recombinant LV with a defect in cell entry directly, containing an anti‐HER2 DARPin on the vector envelope with specific tropism to HER2 receptor on HER2‐positive cancer cells. We assumed that this viral vector transduces cells via an endocytosis‐dependent process.

show abstract

“…Current studies have focused on the importance of oncogenes (EGFR, HER-2, K-ras), tumor suppressor genes (p53, FHIT), cell cycle regulators (cyclin D, cyclin E), and micro-RNAs in the development and prognosis of GBC [10]. HER-2 expression evaluation as a biomarker for non-breast cancers has been gaining importance [11]. Among the array of responsible genes, one of the most flagrant genetic aberrations was ascribed to HER-2 in GBC [10].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of HER-2 and p53 Expression in Gallbladder Carcinoma in North Indian Patients

et al. 2016

View full text Add to dashboard Cite

Background/Objective: Proto-oncogenes (HER-2) and tumor suppressor genes (p53) are commonly deregulated in gallbladder cancer (GBC). Available literature discloses skewed data from endemic Asian countries, especially north India. This study evaluates the prognostic significance of HER-2 and p53 in GBC patients from two major hospitals. Methods: Sixty resectable tumor and control specimens were prospectively collected from December 2012 to January 2016. Immunohistochemical staining was done using monoclonal antibodies to semiquantitatively evaluate HER-2 and p53 protein expression. The criterion for HER-2 positivity was set at >30% tumor cells showing complete, membranous staining while p53 positivity was established at <50% tumor cells showing complete nuclear staining. Clinicopathological correlations were drawn with major clinical outcomes. Results: It was observed that 36.67% (22/60) tumor cases and 5% (3/60) control cases showed strong HER-2 overexpression significantly correlating with sex, T-stage, nodal spread and distant metastasis (p < 0.05), while 33.3% (20/60) positivity was observed for p53 in tumor cases and 1.7% (1/60) in control cases. Multivariate analysis showed HER-2 (p = 0.04; hazard ratio: 2.36; 95% confidence interval: 1.04-5.33) and p53 (p = 0.03; hazard ratio: 5.63; 95% confidence interval: 1.21-26.26) expression to be independent prognostic factors. Conclusion: Our study thus suggests the plausible role of HER-2 and p53 expression in worse prognosis of GBC in a north Indian population.

show abstract

HER2: An emerging biomarker in non-breast and non-gastric cancers

Cited by 32 publications

References 140 publications

Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress

Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress

Design and construction of a recombinant lentiviral vector with specific tropism to human epidermal growth factor‐overexpressed cancer cells: Developing a new retargeting system for lentivirus vectors

Prognostic Significance of HER-2 and p53 Expression in Gallbladder Carcinoma in North Indian Patients

Contact Info

Product

Resources

About